Peptide cleavage

Peptide Therapeutics Group plc (LSE: PTE) was to announce today that it will spin out its drug discovery technology platforms into a new company and focus on its core vaccine programs.

PTE also was to announce that it has amended its agreement with Medeva plc (LSE:MDV) so that PTE will have 100 percent of the U.S. marketing rights to Arilvax, a yellow fever vaccine developed by MDV for which PTE previously had 50 percent of U.S. profits. PTE now will retain all the profits in return for paying for all Phase III trial costs and regulatory submission...